{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:13Z","timestamp":1785416653893,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.03.043","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:58:06Z","timestamp":1777046286000},"page":"948.e1-948.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the Mechanisms of Allogeneic NK Cells Combined with Myeloid Cells in Treating Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"32","author":[{"given":"Tian-yao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-yang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Sheng","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-8458","authenticated-orcid":false,"given":"Kai-Xun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jtct.2026.03.043_bib0001","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.3390\/cancers14194756","article-title":"Updates on the management of acute myeloid leukemia","volume":"14","author":"Huerga-Dominguez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2026.03.043_bib0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.043_bib0003","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.043_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.33145","article-title":"Use of hematopoietic cell transplant for hematologic cancers by race, ethnicity, and age","volume":"7","author":"Hahn","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-022-05061-w","article-title":"Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Li","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.043_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221078466","article-title":"Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution","volume":"50","author":"Lin","year":"2022","journal-title":"J Int Med Res"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.043_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e14924","article-title":"Expert consensus on microtransplant for acute myeloid leukemia in elderly patients\u2013\u2013report from the international microtransplant interest group","volume":"9","author":"Ai","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2231733","article-title":"HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia","volume":"28","author":"Tao","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamaoncol.2017.2656","article-title":"HLA-mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia: results from the microtransplantation interest group","volume":"4","author":"Guo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.043_bib0011","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ajh.25780","article-title":"Comparative study of micro-transplantation from HLA fully mismatched unrelated and partly matched related donors in acute myeloid leukemia","volume":"95","author":"Hu","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.043_bib0012","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41409-019-0761-4","article-title":"HLA-mismatched microtransplantation for relapsed or refractory acute myeloid leukemia as a bridge to allogeneic hematopoietic stem cell transplantation","volume":"55","author":"Sidharthan","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"33","key":"10.1016\/j.jtct.2026.03.043_bib0013","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.2012.42.0281","article-title":"HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up","volume":"30","author":"Guo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.043_bib0014","first-page":"1509","article-title":"Hematopoietic stem cell microtransplantation in patients aged over 70 with acute myeloid leukemia: a multicenter study","volume":"13","author":"Hu","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.043_bib0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients","volume":"117","author":"Guo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.043_bib0016","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00277-018-3583-3","article-title":"HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate\/high-risk acute myeloid leukemia","volume":"98","author":"Liu","year":"2019","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.043_bib0017","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jamaoncol.2020.1706","article-title":"Microtransplantation for acute myeloid leukemia: a systematic review","volume":"6","author":"Pan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.043_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000539","article-title":"Current state of nonengrafting donor leukocyte infusion (focus on microtransplantation for acute myeloid leukemia)","volume":"26","author":"Krakow","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.043_bib0019","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12967-022-03437-0","article-title":"Natural killer cells: a promising immunotherapy for cancer","volume":"20","author":"Chu","year":"2022","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.043_bib0021","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/curroncol28020105","article-title":"The advances and challenges of NK cell-based cancer immunotherapy","volume":"28","author":"Kang","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.043_bib0023","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1089\/scd.2019.0295","article-title":"Donor Selection in HLA-mismatched hematopoietic stem cell microtransplantation for acute myeloid leukemia","volume":"29","author":"Hu","year":"2020","journal-title":"Stem Cells Dev"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.043_bib0024","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/stcltm\/szac066","article-title":"Hyper-CVAD-based stem cell microtransplant as post-remission therapy in acute lymphoblastic leukemia","volume":"11","author":"Cai","year":"2022","journal-title":"Stem Cells Transl Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.043_bib0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.043_bib0026","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.03.043_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/tan.13327","article-title":"Activating KIR haplotype influences clinical outcome following HLA-matched sibling hematopoietic stem cell transplantation","author":"Heatley","year":"2018","journal-title":"HLA"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.043_bib0028","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bbmt.2016.12.638","article-title":"Donor killer immunoglobulin-like receptor haplotype B\/x induces severe acute graft-versus-host disease in the presence of human leukocyte antigen mismatch in T cell-replete hematopoietic cell transplantation","volume":"23","author":"Hosokai","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.043_bib0029","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/sj.leu.2404566","article-title":"Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion","volume":"21","author":"Huang","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41421-022-00417-y","article-title":"Decoding lymphomyeloid divergence and immune hyporesponsiveness in G-CSF-primed human bone marrow by single-cell RNA-seq","volume":"8","author":"You","year":"2022","journal-title":"Cell Discov"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.043_bib0031","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","article-title":"T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants","volume":"186","author":"Hirschhorn","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.043_bib0032","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","article-title":"A neutrophil response linked to tumor control in immunotherapy","volume":"186","author":"Gungabeesoon","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.043_bib0033","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41423-024-01244-9","article-title":"Neutrophils in cancer: from biology to therapy","volume":"22","author":"Koenderman","year":"2025","journal-title":"Cell Mol Immunol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:36:48Z","timestamp":1785415008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726002617"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.043","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study on the Mechanisms of Allogeneic NK Cells Combined with Myeloid Cells in Treating Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}